TCu 220C probably leads to lower discontinuation rate due to expulsion (750 days) Tietze‐Potter gross… compared with lippes Loop (moderate certainty).
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
Deferasirox may leads to lower discontinuations compared with deferoxamine (low certainty).
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
Oral showed no clear difference in adverse events requiring discontinuation of antibiotics compared with intravenous antibiotic therapy (low certainty).
Single inhaler therapy leads to lower discontinuation due to adverse events compared with fixed dose ICS (high certainty).
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
The intervention showed no clear difference in discontinuation for adverse events (moderate certainty).
The intervention probably leads to lower adverse events requiring discontinuation [range of median (moderate certainty).
It is very uncertain whether the intervention changes adverse events requiring discontinuation of CSFs (very low certainty).
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with placebo (moderate certainty).